Cycling back to folate metabolism in cancer

Lee Younghwan, Karen H. Vousden, Marc Hennequart

Résultats de recherche: Contribution à un journal/une revueArticle de revueRevue par des pairs

Résumé

Metabolic changes contribute to cancer initiation and progression through effects on cancer cells, the tumor microenvironment and whole-body metabolism. Alterations in serine metabolism and the control of one-carbon cycles have emerged as critical for the development of many tumor types. In this Review, we focus on the mitochondrial folate cycle. We discuss recent evidence that, in addition to supporting nucleotide synthesis, mitochondrial folate metabolism also contributes to metastasis through support of antioxidant defense, mitochondrial protein synthesis and the overflow of excess formate. These observations offer potential therapeutic opportunities, including the modulation of formate metabolism through dietary interventions and the use of circulating folate cycle metabolites as biomarkers for cancer detection.

langue originaleAnglais
Pages (de - à)701-715
Nombre de pages15
journalNature Cancer
Volume5
Numéro de publication5
Les DOIs
Etat de la publicationPublié - 2 mai 2024

Financement

The work was funded by Cancer Research UK grant C596/A26855 and ERC-2020-ADG PancObese 101020641 and supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (CC2073), the UK Medical Research Council (CC2073) and the Wellcome Trust (CC2073). K.H.V. is on the board of directors, is a shareholder of Bristol Myers Squibb and is on the science advisory board (with stock options) of PMV Pharma, Raze Therapeutics, Volastra Pharmaceuticals and Kovina Therapeutics. She is on the SAB of Ludwig Cancer and is a cofounder and consultant (with stock options) of Faeth Therapeutics. She has received research funding from Astex Pharmaceuticals and AstraZeneca and has contributed to CRUK Cancer Research Technology filing patent application WO/2017/144877. The other authors declare no conflicts of interest.

Bailleurs de fondsNuméro du bailleur de fonds
Medical Research Council
Astex pharmaceuticals
Wellcome Trust
AstraZeneca NV
Horizon 2020 Framework Programme101020641
Cancer Research UKC596/A26855, WO/2017/144877, ERC-2020-ADG PancObese 101020641
Francis Crick InstituteCC2073

    SDG des Nations Unies

    Ce résultat contribue à ou aux Objectifs de développement durable suivants

    1. SDG 3 - Bonne santé et bien-être
      SDG 3 Bonne santé et bien-être

    Empreinte digitale

    Examiner les sujets de recherche de « Cycling back to folate metabolism in cancer ». Ensemble, ils forment une empreinte digitale unique.

    Contient cette citation